A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors (Q34872658)

5 August 2017

A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors (English)

1 reference

5 August 2017

1 reference

0 references

1 reference

Marcio H Malogolowkin

2

object named as

Marcio Malogolowkin

1 reference

5 August 2017

Rajkumar Venkatramani

1

1 reference

5 August 2017

Tom B Davidson

3

1 reference

5 August 2017

William May

4

1 reference

5 August 2017

Richard Sposto

5

1 reference

5 August 2017

Leo Mascarenhas

6

1 reference

5 August 2017

language of work or name

English

0 references

publication date

22 July 2013

1 reference

5 August 2017

1 reference

5 August 2017

8

1 reference

5 August 2017

e68416

1 reference

5 August 2017

7

1 reference

Creative Commons Attribution 4.0 International

5 August 2017

start time

22 July 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Bevacizumab in recurrent high-grade pediatric gliomas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

A phase I study of irinotecan in pediatric patients: a pediatric oncology group study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

8 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0068416

Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0068416

Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0068416

A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0068416

Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0068416

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0068416

Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3718768

Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study

26 October 2018

1 reference

12 December 2020

Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children

1 reference

12 December 2020

Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor

1 reference

12 December 2020

Suppression of primary tumor growth in a mouse model of human neuroblastoma

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0068416

Identifiers

DOI

1 reference

5 August 2017

0 references

1 reference

5 August 2017

1 reference